A B S T R A C T In normal plasma, the ratio of the procoagulant activity of factor VIII (VIIIAHF) to that of the von Willebrand factor activity (ristocetin cofactor, VIIIVwF) or factor VIII antigen (VIIIAGN) is -1, but ratios >1 (e.g., VIIIAHF > VIIIVwF or VIIIAGN) may be observed in some patients with von Willebrand's disease and in the "late" posttransfusion plasmas of patients with this disorder. The lability of VIIIAHF was studied by incubating plasma, diluted 1:10 in imidazole buffer pH 7.1, for 6 h at 37°C. With normal plasmas, 77+12% (SD) of the original VIIIAHF activity remained after incubation. VIIIAHF was labile (e.g., 35 -55% residual activity) in the "late" posttransfusion plasmas (VIIIAHF> VIIIVwF) of a patient with von Willebrand's disease, but not in the "early" posttransfusion plasmas (VIIIAHF VIIIVwF). VIIIAHF was also labile in the (base-line) plasmas of three patients with von Willebrand's disease in whom the ratios of VIIIAHF to VIIIVWF were 4.4 to 8.1, but not in the plasmas of four other patients in whom the ratio was -1. The electrophoretic mobility of factor VIII antigen was increased in two of the three patients with labile VIIIAHF. In both of these patients, and in the late posttransfusion plasmas, labile VIIIAHF activity could be stabilized by the addition of purified von Willebrand factor (lacking VIIIAHF activity) or (1, 2) . The levels of these two activities in plasma can be quantified by biologic assays in which the activity of pooled normal plasma is designated as 100% activity. In normal plasmas, the ratio of these two activities is generally close to 1.0 (3, 4 (5, 6) . Injection of epinephrine into some patients with this disorder may also result in a disproportionate increase in VIIIAHF levels (7) . Another type of dissociation has been observed in some patients with von Willebrand's disease who show levels of VIIIAHF that are relatively higher than those for VIIIVwF (3, 4, (8) (9) (10) or both VIIIVwF and VIIIAGN (3, 11, 12) . Finally, the two biologic activities of normal factor VIII can be dissociated under conditions of high ionic strength, the activity of VIIIAHF appearing with those of lower molecular weight proteins, while that of VIIIVwF retains its high molecular weight characteristics (4, 6, (13) (14) (15) (16) (17) (18) . In this study, we present evidence that in all the above circumstances, the activity of VIIIAHF is relatively more labile and can be stabilized by the addition of the von Willebrand factor, or by hemophilic plasma which contains von Willebrand factor activity. By contrast, no stabilization was obtained with plasma of patients with severe von Willebrand's disease. This stabilizing effect of the von Willebrand factor may have implications regarding the pathogenesis of the latter disorder.
METHODS

Nomenclature and assay of the factor VIII complex
The biologic components of the factor VIII complex are referred to as the antihemophilic factor (AHF) and the von Willebrand factor (VWF) and their respective activities are designated as follows: VIIIAHF is the procoagulant activity of factor VIII that corrects the coagulation defect in hemophilia, as measured by a one-stage method using the kaolinactivated partial thromboplastin time (3) and a Sherwood Lancer Coagulizer (Sherwood Medical Industries, Inc., St. Louis, Mo.) to read the end point; VIIIVWF is the activity of factor VIII in plasma that is required for ristocetin-induced platelet aggregation, assayed by a washed platelet system described previously (3) . Factor VIII antigen, or VIIIAGN, is the antigen present in human plasma recognized by an antibody to human factor VIII and quantified by radioimmunoassay (19) . The minimal sensitivities of these assays of these three components of the factor VIII complex are 1, 3, and 0.3 U/100 ml, respectively.
Preparation and storage of plasma
Venous blood was collected with 1/10 vol of 3.2% sodium citrate in polypropylene tubes (Ivan Sorvall, Inc., Norwalk, Conn.) and centrifuged at 2,400 g and 4°C for 30 min. The platelet-poor plasma was removed and assayed for VIIIAHF activity against pooled normal plasma, as previously described (3). Aliquots were frozen at -700C for subsequent determination of VIIIvwF and VIIIAGN-
Buffers
One part of a stock solution of 0.25 M imidazole of varying pH value was mixed with either four parts of normal saline (0.05 M imidazole-saline), nine parts of saline (0.025 M imidazole-saline), or nine parts of distilled water (0.025 M imidazole).
Determination of VIIIAHF stability
The stability of VIIIAHF activity at 37°C was determined by incubating plasma, diluted 1:10 in 0.05 M imidazole-saline buffer for varying periods of time in polystyrene tubes (Falcon Plastics, Div. BioQuest, Oxnard, Calif.) and determining VIIIAHF values (without further dilution) on the incubated specimens. The dependence ofVIIIAHF stability on pH was determined by making the initial dilutions in buffers of varying pH, incubating for 4 h, and determining the residual VIIIAHF activity. Time-dependent VIIIAHF stability was determined with imidazole-saline buffer of pH 7.1 as the initial diluent and incubating for 0, 1, 2, 4, and 6 h. (The pH of the plasma-buffer mixtures did not differ by more than 0.04 pH U from that of the buffer alone.) The VIIIAHF activity in the incubated specimen was assayed and then expressed as a percentage of the initial (zero time) activity. In several studies, the buffer that was used to dilute the plasmas contained 0.1% sodium azide in order to eliminate the possibility that the lability of VIIIAHF might be the result of bacterial growth and proteolysis during the incubation period.
Cryoprecipitability of VIIIAHF
In preliminary studies on normal plasma, we found the following method yielded the maximum amount of VIIIAHF in the cryoprecipitate and the maximum total recovery (cryoprecipitate plus supemate). A 12 x 75-mm polypropylene tube (Falcon Plastics) containing 2 ml of fresh plasma was placed in a -70°C freezer and kept there for at least 18 h. (Storage for up to 10 days did not affect the results.) The tube containing the frozen plasma was immersed in an ice bath and kept in a refrigerator for 3 h, after which time it was centrifuged at 2,400 g and 4°C for 15 Analytic Inc., Fort Lee, N.J.) activity was removed and used in stabilization studies to be described. This fraction was devoid of any VIIIAHF activity but contained von Willebrand activity (see Table I ). A (Fig. 1 A) . Electrophoresis ofthe reduced sample disclosed the presence of a single faintly stained protein that entered the gel (Fig. 1 B) and had an apparent molecular weight (21) Chromatography of plasma on Bio-Gel A-15m
8 ml of plasma were applied through a flow adapter to the top of a 2.6 x 40-cm siliconized glass column packed to a height of 28.5 cm with Bio-Gel A-15m that had been previously equilibrated with 0.025 M imidazole-saline, pH 7.1, FIGURE 1 Electrophoresis of purified von Willebrand factor on SDS-polyacylamide gel. The gel on the left (1 A) was obtained with an unreduced sample; the sample on the right (1 B) was obtained after reduction with /3-mercaptoethanol.
containing 0.1% bovine albumin (Sigma Chemical). A flow rate of 0.7 ml/min was maintained by means of a Mariotte flask using an outlet pressure of 100 cm H20. The amount of VIIIAHF in each fraction was determined from a standard curve constructed by diluting control plasma in imidazolesaline buffer containing 0.1% bovine albumin, and the activity in each fraction was expressed as a percent of the total recovered VIIIAHF activity. The elution pattern of VIIIAHF was characterized by calculating the VIIIAHF activity recovered in three summed fractions: I was the total activity in fractions 11-14, the first four fractions in which OD2.0 was detectable;
II was the activity in fractions [15] [16] [17] [18] ; III was the activity in fractions 19-22. In seven normal plasmas, the percents of the total VIIIAHF activity recovered in pools I, II, and III were 84.1+6 (SD), 8 .36±1.3, and 3.57±1.14%, respectively.
Mobility offactor VIJI-related antigen on crossed immunoelectrophoresis
This was carried out in 0.9% agarose (Indubiose A37) using 5 x 7.5-cm glass slides. The buffer used for the preparation of the agarose and in the reservoirs was 0.025 M barbital, pH 9.5. Approximately 1 ,ul of Evan's blue dye was added to 30 yl of plasma in a 5-mm well before electrophoresis at 8 V/cm (46 mA) for 1 h in a water-cooled electrophoresis chamber. The migration of Evans blue dye bound to albumin was measured (3.75-4 .00 cm) before the agarose was removed from the top three-quarters ofthe slide and replaced by 4 ml of0.9%o of agarose containing a 1:500 dilution of rabbit antifactor VIIIrelated antigen (19) . Electrophoresis of the proteins into the agarose containing antibody was carried out at a constant current (1.8 mA/cm) for 20 h in the water-cooled chamber. The plate was then rinsed briefly in 0.5 M NaCl, 0.05 M phosphate, pH 7.2, and in distilled water before drying and staining with Coomassie Blue (28) . VIIIAGN mobilities of plasmas are expressed as a ratio of the migration distance of the peak of the immunoprecipitate from the origin divided by the migration distance of albumin in that plasma. In order to concentrate plasmas with very low content of factor VIII-related antigen, an equal volume of 20% ethylene glycol 6,000 (J. T. Baker Chemical Co., Phillipsburg, N.J.) was first added. After continuous mixing for 1 h at 4°C, the precipitate was separated by centrifugation at 3,000g for 20 min at 4°C. The precipitated proteins were dissolved in the barbital buffer (1/10 of the original plasma volume was added; the concentration of antigen in the dissolved precipitate was five times that of the starting plasma). In studies on five normal subjects, the average crossed immunoelectrophoresis mobility of factor VIII antigen in frozen plasma was found to be 97% (range 84-113%) of that in polyethylene glycol concentrate obtained from that plasma. Table II. Patients with "mild" von Willebrand's disease. Seven patients with the typical findings of a prolonged bleeding time and decreased levels of the factor VIII complex (Table III) were studied. Levels of VIIIAHF activity in these patients ranged from 30-50 U/100 ml, levels of VIIIVwF were 6-46 U/100 ml, and those of VIIIAGN were 2-43 U/100 ml. (3) .
Plasmas used in study
Normal subjects. Plasmas from healthy hospital employees were used as controls.
Other plasmas used in study Plasmas of four patients with severe hemophilia (VIIIAHF deficiency) were used as a source of von Willebrand factor in some studies. As controls for these studies, we used plasmas from three patients with severe von Willebrand's disease. The values of the factor VIII complex in these seven patients are shown in Table IV .
RESULTS
Stability of VIIIAHF in normal plasmas. In preliminary studies, incubation of plasma from 16 normal subjects for 4 h in buffers of varying pH values showed that VIIIAHF activity was best maintained in the pH range of 6.9-7.25 ( Fig. 2 A) , similar to findings in previous studies (29, 30) . For determining sequential loss of VIIIAHF activity in plasma during incubation at 370C, we elected to use a buffer of pH 7.1. The sequential loss of activity in normal plasma during 6 h of incubation at this pH value is shown in Fig. 2 and VIIIAGN were declining. In transfusion study I, the levels of VIIIAHF in the 1-h and 48-h posttransfusion samples were almost identical (29 and 28 U/100 ml, respectively). However, VIIIVWF and VIIIAGN levels in the 1-h posttransfusion plasma were 39 and 27 U/100 ml, whereas the levels in the 48-h plasma were <3 and 3 U/100 ml, respectively, for these factors. The stability of VIIIAHF activity in these two plasmas were studied on aliquots that had been frozen at -70°C for 5-10 days.
(VIIIAHF values on these stored plasma specimens were virtually identical to those obtained on the fresh specimens before freezing.) Incubation of these plasmas (diluted with 1:10 in imidazole-saline, pH 7.1) for 6 h (Fig. 3 A) showed that VIIIAHF activity in the 48-h (von Willebrand factor-poor) plasma was strikingly labile, whereas the activity in the 1-h (von Willebrand factor-rich) plasma was similar to that of normal plasma. The results were entirely similar with the plasmas obtained after transfusion study IL. In this study, a progressive dissociation of the values of the factor VIII complex also occurred (Table I) ; for example, 78 h after the transfusion, the VIIIAHF level was 95 U/100 ml, while that of VIIIVWF and VIIIAHF was 36 and 28 U/100 ml, respectively. As in study I, the VIIIAHF activity was more labile in the late (e.g., 30, 54, and 78 h) posttransfusion plasmas that were (relative to VIIIAHF) von Willebrand-poor than the 5-h plasma (Fig. 3 B) . In the latter plasma, the stability of VIIIAHF activity was normal.
The VIIIAHF activity in the 48-h posttransfusion I plasma could be stabilized by the prior addition of purified von Willebrand factor (Fig. 4 A) , which increased the VIIIvWF and VIIIAGN levels to 51 and 69 U/100 ml, without any detectable effect on the VIIIAHF level (Table I and Fig. 4 A) . Plasmas from hemophilic patients (which contain the von Willebrand factor; Table IV) also stabilized VIIIAHF activity in the 48-h posttransfusion I plasma, whereas plasmas from three patients with severe von Willebrand's disease (Table  IV) were without effect (Fig. 4 B) .
The 
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showed that, in addition to being more labile, the VIIIAHF activity in late posttransfusion plasma also eluted differently from Bio-Gel A-15m than that in normal or early posttransfusion plasma. As seen in Table II and Fig. 6 , 84±3% (SD) of the recovered VIIIAHF activity from normal plasma eluted in the void volume. In plasma obtained 30, 72 , and 96 h after transfusion, the void volume VIIIAHF was 72, 62, and 53%, respectively, of its total recovered activity. Note, however, that although a greater percentage of the VIIIAHF activity in the late posttransfusion samples eluted after the void volume, no sharp peak of lower molecular weight activity was observed. In addition, when these post-void volume fractions were pooled, concentrated in cellophane membranes (Spectrapor, Fisher Scientific Co., Pittsburgh, Pa.) against polyethylene glycol flakes (mol wt 20,000), and chromatographed on Bio-Gel A-15m in the presence of 0.002 M CaCl2, which prevents re-aggregation of low molecular weight factor VIII (31), the VIIIAHF activity continued to elute after the void volume, but again, no sharp peak was observed. Measurements of the mobility of factor VIII antigen in 3-, 24-, and 48-h posttransfusion plasmas showed a progressive increase in mobility (Table II and Fig. 7) . Mobilities in the 72-, 79-, and 96-h specimens would have required concentration of the plasmas, which was precluded by the limited volume of the samples available.
Increased lability of VIIIAHF activity in patients with von Willebrand's disease who have "aberrant" von Willebrand factor. The stability of plasma VIIIAHF activity at pH 7.1 was studied in seven patients (Table III) with "mild" von Willebrand's disease. Results are shown in Fig. 8 . In four patients, stability of VIIIAHF was either normal or only slightly decreased (Fig. 8, open circles) . In these four patients, the average ratio of VIIIAHF activity to that of VIIIVwF or VIIIAGN was 1.2 and 1.3, respectively, and in no individual was this this ratio >1.6. The VIIIAHF activity was strikingly more labile in the plasma of the three other patients (Fig. 8, closed circles) , in whom the ratios ofVIIIAHF to VIIIVWF and/or VIIIAGN were greater, averaging 4.7 and 8.1, respectively. In two of these patients (J.L. and A.S., the third patient, J.M., was not studied), the elution pattern ofVIIIAHF after chromatography of plasma on Bio-Gel A-15m was different than a-4;-so A INCUDATION TIME (h) FIGURE (Fig. 9 A) and by plasmas of patients with hemophilia ( Fig. 9 B) . In contrast, plasmas of patients with severe von Willebrand's disease were without effect (Fig. 9 B) Fig. 11 . The VIIIAHF activity appeared to be more stable than that in native, normal plasma; therefore, longer incubation periods (24-48 h ) were required to demonstrate significant loss of activity. Nevertheless, even with these modified conditions of incubation, the VIIIAHF activity of "low molecular weight factor VIII" was considerably more stable in hemophilic plasma than in the plasma of patients with von Willebrand's disease (Fig. 11) .
Cryoprecipitability of VIIIAHF activity. As shown in Table II , the ratio of VIIIAHF in the cryoprecipitate to that in the supernate (C/S) was 3.7±+1.3 (SD) in normal subjects. In four patients with von Willebrand's disease, the C/S ratio was within the mean ±2 SD values of normal subjects. The cryoprecipitability of VIIIAHF was low in the three patients with "labile" VIIIAHF and low VIIIVWF/VIIIAGN values. In patient J. L., cryoprecipitability was only moderately reduced (C/S = 1.0), whereas strikingly low values (0.3 and 0.1) were obtained in patients J. M. and A. S. When the plasma of patient A. S. was mixed with equal parts of hemophilic plasmas before freezing, the C/S ratio increased to 0.5 (mean of three different plasmas), whereas it remained 0.1 when mixed with plasmas of patients with von Willebrand's disease. Decreased cryoprecipitability was also found in the late posttransfusion plasmas (patient V. M.) that were relatively deficient in VIIIVWF activity (Table I) Attempts to stabilize VIIIAHF activity in normal plasma. The addition of the following substances to normal plasma did not stabilize the VIIIAHF activity during 6 h ofincubation: heparin (0.025 and 0.05 U/ml), Trasylol (100 U/ml), E-amino caproic acid 0.05 M, STI (10-4 M), or benzamidine HCl (10-4 M) . The presence of sodium azide in the diluting buffer did not increase the stability of VIIIAHF in either normal plasma, the plasma of patient A. S., or late posttransfusion plasmas showing increased VIIIAHF lability.
DISCUSSION
The structure-function relationships of factor VIII that determine the plasma levels of VIIIAHF, VIIIVwF, and VIIIAGN are not clear. It is generally agreed that VIIIAGN is a property of a 1.2 x 106 dalton molecule that is composed of 200,000 mol wt subunits and possesses VIIIVWF activity as well (2, 32) . Thus, impaired association of abnormally charged subunits (9, 10, 33, 34) NORMAL ELUTION VOLUME (ml) FIGuRE 6 Chromatography of normal and posttransfusion plasmas on Bio-Gel A-15m. 8 ml of plasma was chromatographed on Bio-Gel A-15m (2.6 x 28.5 cm). In normal plasma, 84±3% (SD) of the recovered VIIIAHF is eluted as a sharp peak in the void volume (see Table II ). In the late (72 and 96 h) posttransfusion (T.) III plasmas of patient V. M., a relatively lesser percent of the recovered activity was found in the void volume (see also Table III ). The mixture was diluted with 3.2 ml of 0.05 M imidazole-saline, pH 7.2, and incubated at 37°C. Initial VIIIAHp activity was 12 U/100 ml. 
